NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; CompensatoryArrangements of Certain Officers.
NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
2016 Bonus Awards for Executive Officers
On April 25, 2017, the Compensation, Nominating and Governance (“CNG”) Committee of the Board of Directors of Navidea Biopharmaceuticals, Inc. (the “Company”) determined to pay a cash bonus to each of Michael M. Goldberg, M.D., the Company’s President and Chief Executive Officer, in the amount of $110,684.93, and Jed A. Latkin, the Company’s Interim Chief Operating Officer and Chief Financial Officer, in the amount of $122,903.23 for the year ended December 31, 2016. As previously reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2017, the CNG Committee had deferred determination of 2016 bonus awards to each of Dr. Goldberg and Mr. Latkin pending the closing of the Company’s sale of certain assets to Cardinal Health 414, LLC, which occurred on March 3, 2017.
About NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB)
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson’s disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Recent Trading Information
NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) closed its last trading session up +0.002 at 0.496 with shares trading hands.
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson’s disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) Recent Trading Information
NAVIDEA BIOPHARMACEUTICALS, INC. (NYSEMKT:NAVB) closed its last trading session up +0.002 at 0.496 with shares trading hands.
